Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX - Free Report) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Perspective Therapeutics' FY2024 earnings at ($0.90) EPS and FY2025 earnings at ($1.09) EPS.

Several other equities research analysts have also weighed in on CATX. Oppenheimer dropped their target price on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday, January 24th. Bank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $15.14.

Perspective Therapeutics Trading Down 2.9 %

CATX traded down $0.10 on Wednesday, hitting $3.31. 519,575 shares of the company were exchanged, compared to its average volume of 988,394. The business's fifty day moving average is $3.45 and its 200 day moving average is $9.13. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, research analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares of the company's stock, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Henson acquired 25,975 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was bought at an average cost of $3.85 per share, with a total value of $100,003.75. Following the acquisition, the director now owns 25,975 shares in the company, valued at $100,003.75. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE boosted its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after purchasing an additional 3,866 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Perspective Therapeutics in the 4th quarter valued at $33,000. Intech Investment Management LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth $137,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $34,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.